Skip to main content

Table 1 Clinicopathological features of BC patients from TCGA dataset

From: Overexpressed VDAC1 in breast cancer as a novel prognostic biomarker and correlates with immune infiltrates

Clinicopathological features Low expression of VDAC1 High expression of VDAC1
n 532 533
Age, n (%)
 ≤60 297 (27.9%) 291 (27.3%)
 >60 235 (22.1%) 242 (22.7%)
T stage, n (%)
 T1 147 (13.8%) 128 (12.1%)
 T2 294 (27.7%) 321 (30.2%)
 T3 68 (6.4%) 69 (6.5%)
 T4 23 (2.2%) 12 (1.1%)
N stage, n (%)
 N0 258 (24.7%) 249 (23.8%)
 N1 180 (17.2%) 169 (16.2%)
 N2 52 (5%) 64 (6.1%)
 N3 34 (3.3%) 40 (3.8%)
M stage, n (%)
 M0 431 (47.4%) 458 (50.4%)
 M1 9 (1%) 11 (1.2%)
Pathologic stage, n (%)
 Stage I 94 (9%) 86 (8.3%)
 Stage II 308 (29.6%) 298 (28.6%)
 Stage III 111 (10.7%) 127 (12.2%)
 Stage IV 9 (0.9%) 9 (0.9%)
ER status, n (%)
 Negative 138 (13.6%) 99 (9.7%)
 Positive 375 (36.9%) 403 (39.6%)
PR status, n (%)
 Negative 187 (18.4%) 151 (14.9%)
 Positive 323 (31.8%) 351 (34.5%)
HER2 status, n (%)
 Negative 293 (40.9%) 255 (35.6%)
 Positive 62 (8.6%) 95 (13.2%)